chronic-obstructive-pulmonary-disorder-market
Published

October 2017

Global Chronic Obstructive Pulmonary Disorder Market – Growth, Trends and Forecasts (2017 – 2022)

Purchase Report
$4250
Single user license
$4500
Team license
$8750
Corporate license

Chronic Obstructive Pulmonary Disorder Market

The global COPD therapeutics market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was estimated to be USD XX million in 2015 and is forecasted to reach USD XX million by 2021.

The growth of the global chronic obstructive pulmonary disease (COPD) market is expected to be fueled by a high number of new, more efficacious and convenient products entering the market and commanding a greater value compared to the therapies already existing in the market. Another major factor propelling the growth of the market is the introduction of novel innovations like ultrasonic nebulizers, which are superior to the existing jet nebulizers. The competitive environment is expected to intensify with an increase in product extensions, technological innovations, and an increase in the number of mergers and acquisitions. The market for COPD drugs shows potential opportunity in both developed and developing countries. Due to the effectiveness and advancements in technology, many companies are focusing and collaborating to develop innovative COPD drugs and treatments.

Global COPD Therapeutics - Market Dynamics

The report details several factors driving and restraining the market, some of which are discussed below.

Drivers

  • Technological advancements (e.g. ultrasonic nebulizers)
  • Increasing global spending on medicines
  • Increasing tobacco and cigarette consumption

Restraints

  • Increased pricing pressure
  • Patent expiries
  • Introduction of generic drugs in the market

Market Segmentation

The global COPD therapeutics market has been segmented by drug type and products. By drugs, the market is segmented into Short-Acting Bronchodilators, Corticosteroids, Methylxanthines, Long-Acting Bronchodilators and Phosphodiesterase-4 Inhibitors). The products segment consists of inhalers (MDI’s. DPI’s and SMI’s) and nebulizers (jet nebulizers, ultrasonic nebulizers). The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.

Some of the key players in the market are:

  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Novartis
  • Teva Pharmaceuticals
  • Ache Laboratorios Farmaceuticos
  • Almirall
  • Aquinox Pharmaceuticals
  • Ario Pharma
  • Asmacure
  • Astellas Pharma
  • BioMarck Pharmaceuticals
  • Others

What the Report Offers

  • Market definition, along with identification of key drivers and restraints for the market.
  • Market analysis with region-specific assessments and competition analysis on a global and regional scale.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
  • Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
  • Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.
  • A comprehensive list of key market players, along with the analysis of their current strategic interests and key financial information.
  • An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain critical insight into the factors driving and restraining the market, in addition to opportunities, offered.
RELATED REPORTS
No related reports available.
Purchase Report
$4250
Single user license
$4500
Team license
$8750
Corporate license
Our Clients Include View All

Looking to Customize Report?